Cargando…

Zoledronic acid in the management of metastatic bone disease

Many patients with advanced cancer experience decreased bone strength due to metastatic foci, underlying osteoporosis and/or cancer treatment induced bone loss. The clinical consequences of metastatic disease involving the skeleton are widespread. This review focuses on the efficacy, pharmacology, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Polascik, Thomas J, Mouraviev, Vladimir
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503661/
https://www.ncbi.nlm.nih.gov/pubmed/18728715
_version_ 1782158334159224832
author Polascik, Thomas J
Mouraviev, Vladimir
author_facet Polascik, Thomas J
Mouraviev, Vladimir
author_sort Polascik, Thomas J
collection PubMed
description Many patients with advanced cancer experience decreased bone strength due to metastatic foci, underlying osteoporosis and/or cancer treatment induced bone loss. The clinical consequences of metastatic disease involving the skeleton are widespread. This review focuses on the efficacy, pharmacology, and safety when using intravenous biphosphonate such a zoledronic acid for cancer bone metastases. Zoledronic acid is the gold standard for the medical management of metastatic bone disease. The indications for treatment include prevention of skeletal relevant events (SRE), osteoporotic complications, and palliation of bone pain, among others. Zoledronic acid is the only bisphosphonate effective in decreasing SREs associated with bone metastases from advanced renal cell carcinoma and prostate cancer. Regarding prostate cancer, zoledronic acid effectively prevents both bone loss in patients with locally advanced disease receiving androgen deprivation therapy and SREs in men with hormone-refractory or hormone-sensitive metastatic disease. Zoledronic acid has an acceptable safety profile and tolerability, and has been effective at significantly decreasing the incidence, delaying the onset, and reducing the overall risk of experiencing an SRE compared to placebo. It is the only bisphosphonate currently approved for the prevention and treatment of skeletal complications in patients with bone metastases due to all solid tumors.
format Text
id pubmed-2503661
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-25036612008-08-26 Zoledronic acid in the management of metastatic bone disease Polascik, Thomas J Mouraviev, Vladimir Ther Clin Risk Manag Review Many patients with advanced cancer experience decreased bone strength due to metastatic foci, underlying osteoporosis and/or cancer treatment induced bone loss. The clinical consequences of metastatic disease involving the skeleton are widespread. This review focuses on the efficacy, pharmacology, and safety when using intravenous biphosphonate such a zoledronic acid for cancer bone metastases. Zoledronic acid is the gold standard for the medical management of metastatic bone disease. The indications for treatment include prevention of skeletal relevant events (SRE), osteoporotic complications, and palliation of bone pain, among others. Zoledronic acid is the only bisphosphonate effective in decreasing SREs associated with bone metastases from advanced renal cell carcinoma and prostate cancer. Regarding prostate cancer, zoledronic acid effectively prevents both bone loss in patients with locally advanced disease receiving androgen deprivation therapy and SREs in men with hormone-refractory or hormone-sensitive metastatic disease. Zoledronic acid has an acceptable safety profile and tolerability, and has been effective at significantly decreasing the incidence, delaying the onset, and reducing the overall risk of experiencing an SRE compared to placebo. It is the only bisphosphonate currently approved for the prevention and treatment of skeletal complications in patients with bone metastases due to all solid tumors. Dove Medical Press 2008-02 2008-02 /pmc/articles/PMC2503661/ /pubmed/18728715 Text en © 2008 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Polascik, Thomas J
Mouraviev, Vladimir
Zoledronic acid in the management of metastatic bone disease
title Zoledronic acid in the management of metastatic bone disease
title_full Zoledronic acid in the management of metastatic bone disease
title_fullStr Zoledronic acid in the management of metastatic bone disease
title_full_unstemmed Zoledronic acid in the management of metastatic bone disease
title_short Zoledronic acid in the management of metastatic bone disease
title_sort zoledronic acid in the management of metastatic bone disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503661/
https://www.ncbi.nlm.nih.gov/pubmed/18728715
work_keys_str_mv AT polascikthomasj zoledronicacidinthemanagementofmetastaticbonedisease
AT mouravievvladimir zoledronicacidinthemanagementofmetastaticbonedisease